Celon Pharma has an agreement with ABM to co-finance the CardioCAPS project with the amount of PLN 12.1 million

Celon Pharma has an agreement with the Medical Research Agency (ABM) to co-finance the CardioCAPS project with the amount of PLN 12.1 million, representing 61.7% of the total eligible costs of the project, the company announced. The project is scheduled to be completed by the end of June 2025.

"Celon Pharma S.A. informs about the signing on December 1, 2022 between the company and the Medical Research Agency of an agreement for the implementation and co-financing of the project 'CardioCAPS - increasing drug safety by implementing Celon Pharma S.A. in its own production. innovative oral forms of three medicinal products used in the pharmacotherapy of cardiovascular diseases. The total eligible cost of the project is PLN 19.6 million.

The aim of the project is to develop new generic products in the field of cardiovascular diseases, in particular to perform clinical bioequivalence studies and to implement a comprehensive portfolio of three new generation anticoagulants, containing three different active substances, each in a wide range of doses.

Celon Pharma is an integrated biopharmaceutical company dealing with research, development, production and sale of pharmaceutical products. It debuted on the main market of the Warsaw Stock Exchange in 2016.

Source
Our privacy policy
%d bloggers like this: